Prinicple Investigator: Shahin Lockman/Scott Dryden Peterson
To compare the incidence of severe/life-threatening anemia occurring from 1 to 6 months of life between infants who do receive cotrimoxazole (CTX) and infants who did not receive CTX prophylaxis, among a group of children who were all exposed to maternal HIV and maternal Highly Active Antiretroviral Therapy (HAART). The study also seeks to identify factors associated with increased early mortality/morbidity in a programmatic cohort of HIV-exposed, predominantly formula-feeding infants.
Enrollment: February 2009–May 2010
Follow Up: Complete October 2010